Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

Completed

Conditions studied: Schizophrenia, Schizoaffective Disorder, Delusional Disorder

In brief

This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls. Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.

Key facts

Study ID

NCT00222807

Run by

University of Pittsburgh

People needed

200

Starts

2003-08-01

Expected to finish

2016-03-01

Last updated by the study team

2017-08-28

Who can join

Age: 14 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association

You may not qualify if…

• Diabetes, type 1 or 2
• Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance use)
• Age above 50 or age below 14

Where it is running

• University of Pittsburgh — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.